Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_assertion type Assertion NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_head.
- NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_assertion description "[The higher signature score in metastatic compared to primary lesions, and the potential link to PI3K activation and EMT, support further studies of ECARS in relation to response to PI3K and EMT inhibitors in clinical trials of metastatic endometrial carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_provenance.
- NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_assertion evidence source_evidence_literature NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_provenance.
- NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_assertion SIO_000772 24995579 NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_provenance.
- NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_assertion wasDerivedFrom befree-2016 NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_provenance.
- NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_assertion wasGeneratedBy ECO_0000203 NP1198653.RAljfv-bojDpYL1KdIQVAqApSoEVZeJeoDL68rDp34WXQ130_provenance.